Health Care [ 6/12 ] | Biotechnology [ 22/75 ]
NASDAQ | Common Stock
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma.
The company offers its products to dermatology and gastroenterology markets.
The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 26 | -0.08 Decreased by -125.00% | -0.35 Increased by +77.05% |
| Nov 3, 25 | -0.02 Decreased by -125.00% | -0.52 Increased by +96.15% |
| Aug 4, 25 | 0.15 Decreased by -51.61% | -0.51 Increased by +129.41% |
| Apr 30, 25 | -0.90 Decreased by -903.89% | -0.07 Decreased by -1.28 K% |
| Feb 26, 25 | 0.32 Increased by +420.00% | 0.04 Increased by +700.00% |
| Nov 4, 24 | 0.08 Increased by +130.77% | -0.06 Increased by +233.33% |
| Aug 5, 24 | 0.31 Increased by +144.29% | -0.27 Increased by +214.81% |
| May 2, 24 | -0.09 Increased by +91.82% | -0.33 Increased by +72.73% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 87.01 M Increased by +0.81% | -2.33 M Decreased by -124.32% | Decreased by -2.68% Decreased by -124.12% |
| Sep 30, 25 | 83.04 M Decreased by -3.19% | -501.00 K Decreased by -122.08% | Decreased by -0.60% Decreased by -122.81% |
| Jun 30, 25 | 86.19 M Decreased by -0.94% | 4.52 M Decreased by -49.29% | Increased by +5.25% Decreased by -48.81% |
| Mar 31, 25 | 87.99 M Increased by +20.57% | -25.85 M Decreased by -920.05% | Decreased by -29.38% Decreased by -745.99% |
| Dec 31, 24 | 86.31 M Increased by +30.54% | 9.59 M Increased by +471.71% | Increased by +11.11% Increased by +384.75% |
| Sep 30, 24 | 85.78 M Increased by +39.50% | 2.27 M Increased by +132.86% | Increased by +2.65% Increased by +123.56% |
| Jun 30, 24 | 87.00 M Increased by +73.53% | 8.92 M Increased by +147.50% | Increased by +10.25% Increased by +127.38% |
| Mar 31, 24 | 72.97 M Increased by +73.59% | -2.53 M Increased by +91.32% | Decreased by -3.47% Increased by +95.00% |